This 1050-page report, with over 300 charts and tables, documents current HTS practices for drug discovery and the evolving role of the HTS laboratory in biotech and pharmaceutical companies, academic centers, and institutes worldwide. This study provides an in-depth analysis of the current levels of success as regards to discovering new drugs using HTS, evolving strategies to increase this success, current and expected use of cell-based assays and high content screening, detection technologies, equipment used, targets and target classes growing in importance, the number of compounds screened, throughput, microplates, budgets and expenditures by product category, outsourcing trend, market size and expected growth, unmet needs in HTS, and the challenges and opportunities in HTS for both users and their suppliers.
Published February 2010.

This 300-page report documents pricing practices, policies, agreements, and strategies for both pharmaceutical and biotechnology companies and contract manufacturers. Learn what pharmaceutical and biotechnology companies are paying contractors for mammalian cell culture, microbial fermentation production, and related services. Per- batch, per time-in-facility, and per-gram prices are analyzed by technology and by tank sizes and both prices paid and prices charged are documented. In addition, the study provides detailed best practices information regarding difficult-to-negotiate issues such as liability for failed batches, down payments, cancellation fees, technology transfer fees, client-caused delays, process development fees, and a lot more. Published September 2008.